<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737332</url>
  </required_header>
  <id_info>
    <org_study_id>CHL-AA-201</org_study_id>
    <nct_id>NCT02737332</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
  <acronym>STAAR</acronym>
  <official_title>A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Churchill Pharmaceutical LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Churchill Pharmaceutical LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the serum testosterone levels in patients with
      Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate as
      Compared to Abiraterone Acetate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is 12-week, open-label study of abiraterone acetate in at least 50 patients with
      metastatic castration-resistant prostate cancer. The primary endpoint is total testosterone
      at pharmacokinetic steady-state. Additional secondary endpoints include safety assessments,
      PSA and pharmacokinetic measurements
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Testosterone levels by intervention</measure>
    <time_frame>Day 10</time_frame>
    <description>Blood Sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA levels by intervention</measure>
    <time_frame>Week 12</time_frame>
    <description>Blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events will be calculated for each body system by treatment group. All Serious Adverse Events and Withdrawals due to Adverse events will be reported by intervention</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Zytiga® (Abiraterone Acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,000 MG (4 x 250 mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoluMatrix™ (Abiraterone Acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 mg (4 x 125 mg qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zytiga® (Abiraterone Acetate)</intervention_name>
    <description>Zytiga® 1,000 mg (4 x 250 mg qd) Compared to SoluMatrix™ Abiraterone Acetate 500 mg</description>
    <arm_group_label>Zytiga® (Abiraterone Acetate)</arm_group_label>
    <other_name>Zytiga®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SoluMatrix™ (Abiraterone Acetate)</intervention_name>
    <description>SoluMatrix™ Abiraterone Acetate 500 mg Compared to Zytiga® 1,000 mg (4 x 250 mg qd)</description>
    <arm_group_label>SoluMatrix™ (Abiraterone Acetate)</arm_group_label>
    <other_name>SoluMatrix™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to any study-related procedure being performed

          2. Male subjects at least 18 years of age or older at time of consent

          3. Pathologically confirmed adenocarcinoma of the prostate

          4. Ongoing therapy with a GnRH agonist or antagonist AND serum testosterone level &lt;50
             ng/dL at screening

          5. Metastatic disease documented by computed tomography (CT)/ magnetic resonance imaging
             (MRI) or bone scan. Imaging obtained within 42 days prior to the start of study
             medication will be accepted.

          6. Meeting disease progression according to the recommendations of the prostate cancer
             working group 2 by one of the following criteria:

               -  Two rises of PSA (taken a minimum of 1 week apart) from a baseline measurement of
                  at least 2 ng/mL,

               -  Imaging progression (CT/MRI) by RECIST criteria

               -  Nuclear scan progression by new lesion.

          7. Discontinuation of flutamide or nilutamide, and other anti-androgens at least 4 weeks
             prior to the start of study medication; discontinuation of bicalutamide at least 6
             weeks prior to start of study medication.

          8. Discontinuation of Radiotherapy &gt; 4 weeks prior to start of study medication.

          9. ECOG performance status of 0-1 at screening

         10. Screening blood counts of the following:

               -  Absolute neutrophil count &gt; 1500/µL

               -  Platelets &gt; 100,000/µL

               -  Hemoglobin &gt; 9 g/dL

         11. Screening chemistry values of the following:

               -  ALT and AST &lt; 2.5 x ULN

               -  Total bilirubin &lt; 1.5 x ULN

               -  Creatinine&lt; 1.5 x ULN

               -  Albumin &gt; 3.0 g/dL

         12. Potassium &gt; 3.5 mmol/L

         13. Life expectancy of at least 6 months at screening

         14. Subject is willing and able to comply with all protocol requirements assessments

         15. Agrees to protocol-defined use of effective contraception.

        Exclusion Criteria:

          1. History of impaired pituitary or adrenal gland function

          2. Prior therapy with abiraterone acetate, orteronel, ketoconazole or any other CYP17
             inhibitor

          3. Prior therapy with enzalutamide

          4. Prior use of experimental androgen receptor antagonist

          5. Previous exposure to Ra-223:Xofigo

          6. Previous chemotherapy

          7. Initiation of bisphosphonate or denosumab therapy within 30 days prior to the start of
             study medication. Patients who are on a stable dose of these medications for at least
             30 days at the time of starting study drug are eligible.

          8. Therapy with estrogen within 30 days prior to the start of study medication

          9. Use of systemic glucocorticoids equivalent to &gt; 10 mg of prednisone daily; patients
             who have discontinued or have reduced dose to &lt; 10 mg prednisone within 14 days prior
             to the start of study medication will be eligible

         10. Prior use of any herbal products that may decrease PSA levels (eg., saw palmetto)
             within 30 days of start of study medication

         11. Known metastases to the brain or CNS involvement

         12. History of other malignancy within the previous 2 years

         13. Major surgery within 30 days prior to the start of study medication

         14. Blood transfusion within 30 days of screening

         15. Serious, persistent infection within 14 days of the start of study medication

         16. Persistent pain that requires the use of a narcotic analgesic

         17. Known gastrointestinal disease or condition that may impair absorption

         18. Treatment with any investigational drug within 4 weeks prior to Day -1 of the study.

         19. Known history of human immunodeficiency virus (HIV) or seropositive test for hepatitis
             C virus or hepatitis B virus

         20. Have poorly controlled diabetes.

         21. Uncontrolled hypertension

         22. History of New York Heart Association (NYHA) class III or IV heart failure

         23. Serious concurrent illness, including psychiatric illness, that would interfere with
             study participation

         24. Inability to swallow tablets whole

         25. Known hypersensitivity to any excipients in study medications

         26. Moderate to severe hepatic impairment (Child-Pugh Classes B and C)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Nemeth, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Churchill Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Nemeth, Ph.D.</last_name>
    <phone>610-382-5613</phone>
    <email>paul@churchillpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alliance Research</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charity Hernandez, LVN</last_name>
      <phone>909-881-0555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Bettino, CCRP</last_name>
      <phone>562-693-4477</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C.</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenden Neeper, MS, CCRP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manatee Medical Research</name>
      <address>
        <city>Brandenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Boucher</last_name>
      <phone>941-792-0340</phone>
      <phone_ext>1328</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Idaho Urology</name>
      <address>
        <city>Coeur D Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Patterson, RN</last_name>
      <phone>208-667-0621</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wichita Urology Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Wheeler, RN, CCRC</last_name>
      <phone>316-636-6100</phone>
      <email>kwheeler@whichitaurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Huskins</last_name>
      <phone>443-471-5750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lincoln Urology, PC</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Weber</last_name>
      <phone>402-489-8888</phone>
      <phone_ext>224</phone_ext>
      <email>lauraw@lincolnurologypc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Tichota</last_name>
      <phone>402-991-8468</phone>
      <email>dtichota@gucancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Urologist of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Clinics of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Rivas</last_name>
      <phone>214-580-1482</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kucenski, CCRC</last_name>
      <phone>757-452-3462</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

